Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical TrialJanuary 3, 2019
CALGARY, Alberta, Jan. 03, 2019 — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb ischemia (“CLI”). In addition, the Company is pleased to provide an update on patient enrollment in the trial.
Medical University of South Carolina is located in Charleston, South Carolina, USA with Dr. Thomas E. Brothers, MD as the principal investigator. Dr. Brothers is a vascular surgeon who focuses on management of circulation and peripheral vascular disease and has been recognized as one of America’s top surgeons and best doctors since 2003. Founded in 1824, the Medical University of South Carolina (“MUSC”) educates and trains more than 3,000 students and 700 residents in six colleges and has nearly 13,000 employees, including approximately 1,500 faculty members. MUSC operates a 700-bed medical center, which includes a nationally recognized children’s hospital, the NCI-designated Hollings Cancer Center, a Level I trauma centre and South Carolina’s only transplant center.
Moses H. Cone Memorial Hospital (“MCMH”) is located in Greensboro, North Carolina, USA with Dr. Vance Wells Brabham IV, MD as principal investigator. Dr. Brabham is a board-certified surgeon who specializes in vascular surgery. His professional interests include complex aortic repair, carotid disease, minimally invasive and surgical treatment of peripheral vascular disease, and venous disease. MCMH is the largest and most comprehensive medical center within its five-county region with a 63-acre campus including a 536-bed teaching hospital and referral center. One of its featured services is the Cone Health Heart Vascular Center. The MCMH has been recognized for heart and vascular care and focuses on clinical trials that have high potential for advancing treatment of heart and vascular disease.
With the addition of these two new sites, the Company has a total of eleven trial sites now open for patient enrollment, of which ten are located in the United States and one in Vancouver, Canada. All sites are actively screening patients for enrollment in the study. In addition, the Company also has seven clinical trial sites located in Canada and the United States that are in various stages of the on-boarding process. The Company specifically targets strategic clinical sites throughout the United States and Canada that serve large populations or have the demographics to support patient enrollment.
Currently a total of twenty four (24) patients have been treated under the clinical trial to-date. The Company anticipates that patient enrollment will escalate rapidly with these additional trial sites on-boarded.
The clinical trial is a randomized, placebo-controlled, double blind Phase II clinical trial to confirm the safety and efficacy of ACP-01. Under the current USA Food and Drug Administration (“FDA”) and Health Canada approved protocol approximately 95 patients will be followed for a minimum period of six months and a maximum of twelve months. The Company’s patented process results in specific stem cells that have the ability to support the generation of new blood vessels to combat the life-threatening complications of CLI. The stem cells are differentiated and expanded from the patient’s blood and then re-injected into the diseased tissue.
“We are excited with the progress we have made on the trial with these two key trial sites located in North and South Carolina being recently on-boarded. Both of these sites have recognized heart and vascular centers with leading vascular surgeons acting as principal investigators. The escalation in site enrollment is a positive indication of the interest in our trial and the need for new treatments for CLI that could offer an alternative to life altering amputations which is currently one of the limited treatment options available for some CLI sufferers,” states Kyle Makofka, President and CEO of Hemostemix.
To download full press release Click Here.
View All News & Media